- Home
- GMAB vs PFG Comparison
GMAB vs PFG Comparison
Compare GMAB & PFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GMAB | PFG |
|---|---|---|
| Founded | 1999 | 1879 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 20.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GMAB | PFG |
|---|---|---|
| Price | $33.84 | $90.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 10 |
| Target Price | $40.00 | ★ $91.30 |
| AVG Volume (30 Days) | ★ 2.0M | 1.3M |
| Earning Date | 02-11-2026 | 02-09-2026 |
| Dividend Yield | N/A | ★ 3.46% |
| EPS Growth | ★ 132.41 | N/A |
| EPS | ★ 25.10 | 6.91 |
| Revenue | $3,845,670,022.00 | ★ $15,800,800,000.00 |
| Revenue This Year | $24.85 | N/A |
| Revenue Next Year | $16.51 | $8.72 |
| P/E Ratio | ★ $13.05 | $13.19 |
| Revenue Growth | ★ 29.57 | 12.33 |
| 52 Week Low | $17.24 | $68.39 |
| 52 Week High | $35.43 | $92.69 |
Technical Indicators
Market Signals| Indicator | GMAB | PFG |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 54.18 |
| Support Level | $30.88 | $87.08 |
| Resistance Level | $35.43 | $92.69 |
| Average True Range (ATR) | 1.01 | 2.05 |
| MACD | -0.09 | -0.09 |
| Stochastic Oscillator | 64.95 | 64.56 |
Price Performance
Historical ComparisonAbout GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About PFG Principal Financial Group Inc
Principal Financial Group Inc is a financial services provider. It offers various financial products and services including retirement, asset management, and workplace benefits and protection solutions to individuals and institutional clients. The company, along with its subsidiaries, operates in the following reportable segments; Retirement and Income Solutions, Principal Asset Management, and Benefits and Protection. Maximum revenue is generated from the Retirement and Income Solutions segment which provides workplace savings and retirement solutions, banking, trust and custodial services, individual variable annuities (including RILAs), pension risk transfer, and investment services to businesses, their employees, and other individuals.